CliffBio
small molecule

IBUPROFEN

IBUPROFEN

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameIBUPROFEN
Active ingredientIBUPROFEN
Strength40MG/ML
Dosage formSUSPENSION/DROPS
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusOTC

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

IBUPROFEN patent cliff — loss of exclusivity — | CliffBio